Literature DB >> 8495303

Treatment of the axilla in patients with screen-detected breast cancer.

J Walls1, C R Boggis, M Wilson, D L Asbury, J V Roberts, N J Bundred, R E Mansel.   

Abstract

Management of the axillary lymph nodes in patients with screen-detected breast cancer is controversial. Optimal treatment should combine accurate determination of node status and avoidance of unnecessary morbidity. This study attempted to determine whether axillary node status could be accurately predicted using selected criteria in women with screen-detected breast cancer. Of 223 breast cancers excised in the Greater Manchester breast screening programme, 180 were invasive and 40 of these had associated lymph node metastases. The presence of involved nodes was associated with large tumour size, high tumour grade and the absence of mammographic microcalcification. Multiple logistic regression analysis revealed that each of these three factors was independently significant. Women with a screen-detected breast cancer < 1 cm in diameter or those with grade I tumours < 3 cm (35 per cent of the total) could be spared axillary surgery with an expected reduction in morbidity and operating time.

Entities:  

Mesh:

Year:  1993        PMID: 8495303     DOI: 10.1002/bjs.1800800409

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  5 in total

1.  Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.

Authors:  I C Smith; K N Ogston; P Whitford; F W Smith; P Sharp; M Norton; I D Miller; A K Ah-See; S D Heys; J A Jibril; O Eremin
Journal:  Ann Surg       Date:  1998-08       Impact factor: 12.969

Review 2.  [Is axillary dissection in clinically lymph node-negative breast carcinoma further indicated?].

Authors:  F K Böhler; H Eiter; W Rhomberg
Journal:  Strahlenther Onkol       Date:  1998-12       Impact factor: 3.621

3.  Diagnostic value of full-dose FDG PET/CT for axillary lymph node staging in breast cancer patients.

Authors:  Till A Heusner; Sherko Kuemmel; Steffen Hahn; Angela Koeninger; Friedrich Otterbach; Monia E Hamami; Klaus R Kimmig; Michael Forsting; Andreas Bockisch; Gerald Antoch; Alexander Stahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-05-05       Impact factor: 9.236

4.  A comparison of axillary node status between cancers detected at the prevalence and first incidence breast screening rounds.

Authors:  P A Holland; J Walls; C R Boggis; F Knox; A D Baildam; N J Bundred
Journal:  Br J Cancer       Date:  1996-11       Impact factor: 7.640

5.  Role of fluorine-18-labeled 2-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography in the evaluation of axillary lymph node involvement in operable breast cancer in comparison with sentinel lymph node biopsy.

Authors:  Vasu Reddy Challa; Anurag Srivastava; Anita Dhar; Rajinder Parshad; Chandrasekhar Bal; Rama Mohan Reddy Gona; Rakesh Kumar; Siddhartha Datta Gupta; Punit Sharma
Journal:  Indian J Nucl Med       Date:  2013-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.